Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
None has been completed, partly because patients with IBD were excluded from the pivotal GLP-1 trials
Available safety data showed no increase in serious cardiovascular events during 68 weeks of treatment
Zhang H, Sturchler E, Zhu J, et al
At the highest dose of 12 mg, participants achieved mean body weight reduction of 16.9% compared to 3.0% with placebo
The expression of pro-inflammatory cytokines was markedly decreased in their liver, epididymal adipose, and quadriceps muscle ( Symptomatic support and immunity improvement are currently the first-line approaches for the treatment of chronic inflammation, mainly because chronic inflammation is often acompanied by disorder of the immune microenvironment
Key Player Analysis Bachem Holding AG Novo Nordisk A/S Eli Lilly and Company HEC Pharma Co
